<DOC>
	<DOCNO>NCT01923116</DOCNO>
	<brief_summary>The objective study ass , phase 1/2 study , safety efficacy synthetic vaccine SLP-HPV-01® HIV+ men CD4 count &gt; 350 x 10E6/l HPV16-induced intra-anal high-grade AIN ( grade 2-3 ) fail , recur previous treatment .</brief_summary>
	<brief_title>Therapeutic HPV-16 Vaccination Treatment Anal Dysplasia</brief_title>
	<detailed_description>Rationale : Since introduction combination antiretroviral therapy ( cART ) , human immunodeficiency virus ( HIV ) -related morbidity mortality considerably decrease . However , result significantly prolong life span HIV-positive patient , new cause morbidity mortality become evident . In particular , anal cancer incidence increase dramatically HIV-positive men . Like cervical cancer , anal cancer causally link infection high-risk papillomaviruses ( HPV ) , precede cancer precursor lesion : anal intraepithelial neoplasia ( AIN ) . Over 90 % HIV-positive MSM persist anal HPV infection , 88 % patient high-risk HPV present , high-grade disease ( AIN 2 3 , HG AIN ) present 25-52 % HIV+ MSM . The majority HG AIN cause HPV type 16 . As cervical intraepithelial neoplasia , early diagnosis treatment AIN advocate prevent malignancy . Several treatment option exist AIN , success rate disappointingly low . An alternative strategy might therapeutic HPV vaccination . In woman vulvar intraepithelial neoplasia ( VIN ) , condition comparable pathogenesis , therapeutic vaccination synthetic long-peptide vaccine SLP-HPV-01® , consist mix long peptides HPV-16 viral oncoproteins E6 E7 , well tolerate , prove effective high percentage woman , durable response , induction HPV-16-specific immunity . Objective : The objective current proposal ass , phase 1/2 study , safety efficacy synthetic vaccine SLP-HPV-01® HIV+ men CD4 count &gt; 350 x 10E6/l intra-anal high-grade , HPV16 positive AIN , fail previous treatment . Study population : HIV-positive MSM CD4 count &gt; 350 cells/ul HPV16-induced intra-anal high-grade AIN ( grade 2-3 ) resistant , recur conventional cauterization form local treatment . During past year study group Academic Medical Center Amsterdam build large cohort well-characterized HIV-positive patient histology-proven AIN . Material store patient lesion . Those patient AIN resistant previous treatment identify . The causative HPV type determine stored biopsy patient , use microdissection ( LCM ) in-situ PCR . Only patient HPV-16-induced lesion ( majority patient ) eligible current study . Study design : : The first phase study dose-response study , four different dosage schedule ( 1,5,10 ; 5,10,20 ; 10,20,40 40,40,40,40 μg SLP-HPV-01® , administer intradermally three-week interval ) , dosage schedule without co-administration pegylated interferon-α ( Pegintron 1 μg/kg s.c. ) day vaccine administration . Each vaccination schedule test 5 patient . The vaccination schedule induce HIV-positive MSM best HPV16-specific response compare woman VIN previous study , consider optimal schedule . The size dose group increase total 20 patient treat additional 15 patient . Intervention : Patients vaccinate 3 4 time 3-week interval SLP-HPV-01® vaccine . High-resolution anoscopy ( HRA ) perform inclusion , repeat 3 , 6,12 18 month . The transformation zone photograph visit . Detailed photos plus biopsy lesion site obtain . From venous blood sample PBMCs obtain first ( pre ) , 3 week first vaccination ( post-1 ) , 3 week second vaccination ( post-2 ) , 3 week third vaccination ( post-3 ) applicable 3 week fourth vaccination ( post-4 ) . Endpoints : The primary clinical end point toxicity/ safety , regression lesion 3 , 6 12 month , assess HRA , biopsies take lesion site . Secondary endpoint regression lesion 18 month HPV16-specific immunity blood measure : i.e . ELISPOT ( IFNg ) ex-vivo detection antigen-specific response multiparametric intracellular cytokine/extracellular activation marker stain determine type ( CD4+ and/or CD8+ ) function ( activation status and/or cytokine ) T-cells respond .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent Age ≥ 18 year HIV+ MSM , CD4 count &gt; 350/ul ( maximum 3 month screen visit ) Biopsyproven intraanal highgrade AIN cause HPV16 , resistant , recur previous treatment cauterization ( local treatment ) , 5FU imiquimod . A patient consider resistant cauterization 2 cauterization session still lesion find . A patient consider resistant 5FU imiquimod 4 month weekly ( multiple day ) application still lesions find . Good performance status ( Karnofsky performance score ≥60 [ scale 0 100 , high score indicate good performance status ] ) Normal pretreatment laboratory blood value describe previously . This mean : Leukocytes &gt; 3 x 109/L , lymfocytes &gt; 1 x 109/L , trombocytes &gt; 100 x 109/L hematocrit &gt; 30 % . Immunosuppressive medication disease associate immunodeficiency Life expectancy &lt; 1 year History anal carcinoma IFNα criterion ( see SmPC ) : severe cardiac , thyroid , hepatic central nervous system disease , include severe depression past . Previous HPV vaccination Currently treat IFNα hepatitis C</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Anal intraepithelial neoplasia</keyword>
	<keyword>HIV</keyword>
	<keyword>HPV</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Treatment</keyword>
</DOC>